Daiichi Sankyo
4568.TApprovedDaiichi Sankyo is a Japanese pharmaceutical giant with over 125 years of medical innovation, operating in 30+ countries and publicly traded on the Tokyo Stock Exchange. The company has pivoted strategically to become a global oncology leader by 2030, leveraging its breakthrough DXd ADC technology platform. With flagship products like ENHERTU (developed with AstraZeneca) showing exceptional results across multiple cancer types, Daiichi Sankyo represents one of the most promising ADC technology platforms in oncology today.
4568.T · Stock Price
Historical price data
AI Company Overview
Daiichi Sankyo is a Japanese pharmaceutical giant with over 125 years of medical innovation, operating in 30+ countries and publicly traded on the Tokyo Stock Exchange. The company has pivoted strategically to become a global oncology leader by 2030, leveraging its breakthrough DXd ADC technology platform. With flagship products like ENHERTU (developed with AstraZeneca) showing exceptional results across multiple cancer types, Daiichi Sankyo represents one of the most promising ADC technology platforms in oncology today.
Technology Platform
DXd ADC Technology - a proprietary antibody drug conjugate platform featuring high drug-to-antibody ratios, novel linker technology, and potent payload delivery for enhanced cancer treatment efficacy.
Pipeline Snapshot
568568 drugs in pipeline, 146 in Phase 3
| Drug | Indication | Stage |
|---|---|---|
| Sitafloxacin + Moxifloxacin Hydrochloride | COPD Exacerbation Acute | Approved |
| colesevelam HCl tablets, and simvastatin tablets + simvastatin tablets and coles... | Hypercholesterolemia | Approved |
| Colesevelam Hydrochloride + Ezetimibe + Simvastatin | Hypercholesterolemia | Approved |
| Placebo & Aspirin + Clopidogrel & Aspirin, Prasugrel & Aspirin | Coronary Artery Disease | Approved |
| Anticoagulant Oral | Atrium; Fibrillation | Approved |
Funding History
1FDA Approved Drugs
5Opportunities
Risk Factors
Competitive Landscape
Daiichi Sankyo competes against major players including Pfizer/Seagen, Genentech/Roche, and emerging ADC developers, but maintains competitive advantages through superior DXd technology, recent favorable patent dispute resolution against Seagen, and strategic partnerships with industry leaders like AstraZeneca.
Company Info
Trading
Contact
Therapeutic Areas
Partners
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile